PP
SGMO

Paloma Partners’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Paloma Partners’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-29,625
Closed -$10.6K – 1622
2024
Q2 		$10.6K Buy
+29,625
New +$16K ﹤0.01% 1206
2020
Q4 		– Sell
-41,710
Closed -$395K – 2160
2020
Q3 		$395K Buy
41,710
+30,402
+269% +$329K 0.01% 1316
2020
Q2 		$101K Buy
+11,308
New +$105K ﹤0.01% 1898
2017
Q1 		– Sell
-22,011
Closed -$67K – 2212
2016
Q4 		$67K Buy
+22,011
New +$80.1K ﹤0.01% 1919
2015
Q3 		– Sell
-50,137
Closed -$556K – 1888
2015
Q2 		$556K Buy
50,137
+37,379
+293% +$482K 0.01% 1036
2015
Q1 		$200K Buy
+12,758
New +$197K 0.01% 1085
2014
Q4 		– Sell
-12,600
Closed -$136K – 1337
2014
Q3 		$136K Buy
+12,600
New +$165K 0.01% 877

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Paloma Partners's SGMO Position: Q3 2024 in Review

Paloma Partners sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2024, closing a stake of 29,625 shares — an estimated $10.6K sold.

Paloma Partners first reported a position in SGMO in Q3 2014 and held it in 7 quarters. The position peaked at $556K in Q2 2015. 103 funds tracked by Wall St. Rank hold SGMO as of Q3 2024.

  • Paloma Partners reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
  • Paloma Partners sold 29,625 SANGAMO THERAPEUTICS INC shares in Q3 2024, an estimated $10.6K.
  • Paloma Partners first reported a position in SANGAMO THERAPEUTICS INC in Q3 2014 and held it in 7 quarters.
  • Paloma Partners's SANGAMO THERAPEUTICS INC position peaked at $556K in Q2 2015.
  • 103 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2024.

Based on Paloma Partners's 13F filing for Q3 2024, filed 14 Nov 2024.